Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Key Points

• Characterization of LAG-3 and PD-L1 gene expression highlights unique immune responses in melanoma.
• Key findings include expression variations that may inform therapeutic strategies for advanced melanoma.
• Data collection involved comprehensive analyses of immune and tumor cell gene expressions related to treatment.
• Insights from these biomarker analyses could lead to improved patient outcomes and tailored therapies.